Home Blog Page 214

AS Watson Launches brand lab to Turn Retail Scale into a Data-driven Brand Growth Engine

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 22 June 2026 – AS Watson Group has launched AS Watson brand lab, a data-driven brand creation and scaling platform designed to systematically identify, develop, and grow brands across its global retail ecosystem. Built on the company’s integrated O+O (Offline plus Online) capabilities, extensive distribution network, and deep consumer insight from over 180 million loyalty members, the platform transforms how brands are brought to market – enabling both the creation of new propositions and the rapid scaling of brands across multiple markets with speed, discipline and consistency.

AS Watson Launches brand lab to Turn Retail Scale into a Data-driven Brand Growth Engine

The initiative formalises capabilities the Group has been building internally, combining data-led demand identification, integrated distribution, and execution across more than 17,000 O+O stores in Asia and Europe.

Over the past two years, AS Watson has introduced more than 4,800 new brands and brand extensions across its network, underscoring the scale of its brand development activity.

From Incubation to Execution

AS Watson brand lab departs from traditional incubator models by embedding brand development directly within AS Watson’s retail ecosystem.

Rather than incubating brands ahead of their market entry, the platform operates inside the market, using real-time customer data, shopping behaviour and category dynamics to inform development decisions.

Dr Malina Ngai, Group CEO of AS Watson, said the model reflects the company’s structural advantage. “We don’t wait for brands to find the market – we build them where demand already exists, and scale them through our ecosystem.”

A Systemised Growth Model

At the core of AS Watson brand lab is an integrated operating model linking insight, creation, distribution, demand activation and scaling.

The platform leverages AS Watson’s over 180 million loyalty members and O+O capabilities to accelerate brand selection and commercial execution.

A Structured Pathway to Scale

Brands within AS Watson brand lab are supported through a structured growth pathway, progressing from early-stage validation to regional scaling and category leadership.

At each stage, brands receive differentiated support across insight, distribution, marketing activation and investment, ensuring resources are focused where the greatest growth potential exists.

This staged approach enables AS Watson to systematically build, scale and prioritise brands, improving success rates while maintaining disciplined capital allocation.

Focus on High-Growth Segments

AS Watson brand lab will prioritise product segments including Asian beauty trends (K-beauty, J-beauty, C-beauty), ingredient-led skincare, health and wellness products and elevated personal care – areas where consumer demand continues to evolve rapidly.

The Group expects the platform to strengthen its ability to build proprietary and exclusive brands while improving speed-to-market and capital efficiency.

Proven Brand Scaling in Action

Early outcomes demonstrate how AS Watson brand lab translates insight into accelerated growth – not only by shaping brand development, but by scaling brands rapidly across markets through its integrated O+O ecosystem.

Across multiple categories and geographies, the platform has enabled brands to move from targeted market entry to multi-market expansion with speed and discipline:

COSRX (K-Beauty)– By combining COSRX’s innovation-led skincare expertise with
AS Watson’s extensive retail footprint and deep consumer insights, the partnership has accelerated international expansion and broadened consumer reach. This illustrates how the platform converts strong brand propositions into sustained category growth across markets.

&honey (J-Beauty) – Leveraging its distinctive product positioning alongside
AS Watson’s regional scale, &honey rapidly expanded beyond its home market, rolling out across multiple Asian markets within a short timeframe. This demonstrates the platform’s ability to systematically scale proven domestic leaders into regional brands.

e.l.f. Cosmetics (US) – Through partnership with AS Watson, e.l.f. has extended its community-led, value-driven model across Europe, translating strong brand engagement into measurable market penetration. The example highlights how consumer-centric brands can be amplified through local market execution at scale.

essence (Germany) – The expansion of essence across multiple markets, including exclusive partnerships, reflects how purpose-driven brands can achieve consistency and reach when supported by integrated distribution and retail insight. This underscores the platform’s ability to build sustained brand relevance and loyalty across diverse markets.

Across these examples, brands have scaled through a consistent model – combining data-led selection, integrated distribution, and coordinated market execution – demonstrating how AS Watson brand lab functions as a repeatable engine for brand growth, from market entry through to regional scale.

Scaling a Repeatable Engine

AS Watson brand lab positions AS Watson to leverage its retail footprint not only as a distribution channel, but as an engine for brand creation and scaling.

The initiative signals a shift from opportunistic brand sourcing towards a structured, repeatable growth model, reinforcing AS Watson’s ability to scale brands with speed, discipline and consistency while driving long-term portfolio value.

AS Watson continues to engage with selected brand partners and emerging brands aligned with its focus areas, with further information available through its official
AS Watson brand lab platform (https://www.aswatson.com/asw-brand-lab)

Hashtag: #ASWatson

The issuer is solely responsible for the content of this announcement.

About AS Watson Group

Established in 1841, AS Watson Group is one of the world’s longest-standing and most recognised retail companies with roots in Asia. Today, the company operates over 17,000 stores across 12 retail brands in 31 markets, employing 130,000 people globally. This makes AS Watson Group the largest international health and beauty retailer in the world.

In the fiscal year 2025, AS Watson Group reported revenue of over US$26 billion. The company’s technology-enabled O+O (Offline plus Online) platforms serve over 6 billion shoppers annually, seamlessly integrating physical and digital retail experiences.

AS Watson Group supported over 180 charitable and non-profit organisations every year, dedicating over 40,000 hours of volunteer work to serve over 370,000 people in need in our operating markets.

AS Watson Group is also a member of the world-renowned multinational conglomerate CK Hutchison Holdings Limited, which has four core businesses – ports and related services, retail, infrastructure and telecommunications in over 50 countries.

Please visit for more information.

RZOLV Technologies Completes NRC IRAP-Supported R&D Project for Non-Cyanide Gold Extraction Technology

By
Advertorial Desk
-
Vancouver, British Columbia – Newsfile Corp. – June 22, 2026 – RZOLV Technologies Inc. (TSXV: RZL) (OTCQB: RZOLF) (FSE: S711) (“RZOLV” or the “Company”) is pleased to announce that its wholly owned operating subsidiary, Innovation Mining Inc. (“Innovation Mining”), has completed its first research and development project supported by the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”).

Innovation Mining received advisory services and funding from NRC IRAP to support a research and development project focused on the Company’s proprietary RZOLV™ non-cyanide gold extraction technology. The completed work included bench-scale evaluation of electrochemical regeneration, reagent-management approaches, and process-control conditions intended to inform future closed-loop testing and pilot-scale evaluation. The project generated internal technical information to support continued process development but did not include commercial-scale demonstration or a determination of commercial performance.

The Company believes completion of the project has strengthened its internal technical capacity and provided additional bench-scale development information to support further evaluation of the RZOLV technology platform.

As a result of the project, the Company has expanded its internal technical capabilities through the addition of two full-time employees to its laboratory team. The Company believes this strengthened in-house capacity will support continued research and development, process optimization, and future scale-up activities.

The Company acknowledges the support of NRC IRAP. Hanif Jafari, Chief Technology Officer of RZOLV Technologies, commented: “The completion of this project was valuable for our team as it allowed the Company to carry out focused bench-scale development work while also expanding our laboratory capabilities through the addition of two full-time technical employees. We are grateful to NRC IRAP for its support and for the guidance provided during the project. We look forward to building on this work through further technical evaluation and development of the RZOLV platform.”

The Company intends to continue development work through Innovation Mining, including further technical validation, process optimization, pilot-scale activities, and strategic commercial engagement related to the RZOLV technology platform.

About NRC IRAP

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) supports the growth of innovative Canadian small and medium-sized businesses by providing advisory services, connections and financial assistance. NRC IRAP helps Canadian companies strengthen their technical and innovation capabilities, address business and technology challenges, and advance innovative products and services toward the marketplace.

About RZOLV Technologies Inc.

RZOLV Technologies Inc. is a clean technology company focused on the development and commercialization of alternatives to conventional cyanide-based gold extraction. Through its wholly owned operating subsidiary, Innovation Mining Inc., the Company is advancing its proprietary RZOLV™ technology, a non-cyanide, water-based gold extraction technology under development, designed to reduce reliance on cyanide-based processing in applicable mining applications.

Neither TSX Venture Exchange nor its Regulation Services Provider, as that term is defined in policies of the TSX Venture Exchange, accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Duane Nelson
President & CEO
RZOLV Technologies Inc.
Tel: +1-604-332-2662
Email: duane@rzolv.com

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements in this release include, but are not limited to, statements regarding continued research and development, future technical validation, process optimization, pilot-scale activities, scale-up activities, strategic commercial engagement, potential commercialization, and the future advancement of the RZOLV technology platform.

Forward-looking statements are based on assumptions that management considers reasonable as of the date of this news release, including assumptions regarding the availability of funding, personnel, laboratory and pilot-scale equipment, technical data, third-party testing and validation resources, commercial partner interest, regulatory and environmental assessment requirements, and the Company’s ability to continue advancing its technology platform.

Actual results may differ materially from those expressed or implied by forward-looking statements due to risks and uncertainties, including risks related to technology development, scale-up from laboratory testing to pilot-scale and commercial applications, reagent consumption, electrochemical regeneration performance, process-control requirements, environmental and regulatory considerations, availability of capital, availability of qualified personnel, intellectual property protection, third-party validation, commercial partner adoption, market acceptance, and general business, economic and capital market conditions.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Hashtag: #RZOLVTechnologiesInc

The issuer is solely responsible for the content of this announcement.

CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors

By
Advertorial Desk
-

SHANGHAI, June 22, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration (“NMPA”) today, the New Drug Application (“NDA”) of satricabtagene autoleucel (“satri-cel”), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. Satri-cel is the world’s first approved CAR T-cell therapy product for the treatment of solid tumors.

Gastric cancer is one of the malignancies with the highest disease burden worldwide, ranking fifth in both incidence and mortality globally, with approximately 970,000 new cases and 660,000 deaths annually [1]. More than 70% of new and fatal cases occur in Asia [2], and Chinese patients account for approximately 47% of the global gastric cancer burden [3]. According to statistics from the National Cancer Center of China, there were approximately 360,000 new cases and 260,000 deaths from gastric cancer in China in 2022, ranking fifth in cancer incidence and third in cancer-related mortality [4]. Despite continuous advances in surgical techniques and comprehensive treatment modalities, gastric cancer is insidious in onset. In China, the proportion of early-stage gastric cancer diagnosis remains below 20%, and the 5-year survival rate for advanced gastric cancer is only about 10% [5]. Gastric cancer is characterized by high incidence, low early diagnosis rate, high heterogeneity, and high mortality. Conventional chemotherapy drugs have reached a plateau, targeted therapy options are limited, and the proportion and magnitude of benefit from immunotherapy still urgently need to be improved. Therefore, patients with unresectable or metastatic gastric cancer still face substantial unmet medical needs, and there is an urgent demand to drive the discovery and exploration of more precision therapies and novel anti-tumor agents.

Claudin18.2 is a highly selective marker protein. Its expression in normal healthy tissues is very limited, occurring only in differentiated gastric mucosal epithelial cells, whereas it is highly expressed in gastric cancer and other malignant tumors. Satri-cel is an autologous CAR-T cell product targeting Claudin18.2. It is genetically modified to express a CAR construct consisting of a humanized Claudin18.2-specific single-chain monoclonal antibody fragment (hu8E5-2I), a CD8α hinge region, a CD28 transmembrane region, a CD28 intracellular signaling domain (CD28 ICD), and a CD3ζ intracellular signaling region. To our knowledge, we were the first in the world to successfully identify, validate, and report the solid tumor-associated antigen Claudin18.2 as a valid target for CAR T-cell therapy. To further address the challenges of the tumor microenvironment in treating solid tumors, the company independently developed an innovative, patent-protected preconditioning regimen which is to be administered prior to infusion of satri-cel. This regimen features the addition of low-dose nab-paclitaxel to the conventional lymphodepletion regimen comprising cyclophosphamide and fludarabine to enhance the infiltration and anti-tumor efficacy of CAR T cells. The Company has implemented global patent layout around satri-cel, covering the target, indications, dosage, and preconditioning regimens, among others.

The clinical efficacy of satri-cel has received authoritative recognition from top international medical journals. The results of its confirmatory randomized controlled study have been published in The Lancet [6]. Clinical data show that among patients with advanced, heavily pretreated G/GEJ cancer who have extremely limited treatment options and a very poor prognosis, satri-cel demonstrated significant efficacy benefit and a good safety profile compared to existing treatments, bringing a new treatment option to patients with advanced gastric cancer. This major breakthrough not only establishes a new standard for CAR-T therapy in solid tumors but also lays a solid scientific foundation for advancing to earlier lines of therapy, exploring combination treatment regimens, and expanding applications to other Claudin18.2-positive solid tumors such as pancreatic cancer and biliary tract cancer.

Professor Lin Shen’s team at Peking University Cancer Hospital led the clinical studies of satri-cel. Professor Shen commented, “For patients with advanced G/GEJA who have failed multiple lines of prior therapy, previous treatment options were extremely limited and the prognosis was very poor. The approval of satri-cel provides us with a novel and effective therapeutic weapon. This product has brought clinically meaningful and significant benefits to such patients, with remarkable efficacy that is difficult to achieve with existing treatment modalities. More importantly, as a CAR-T product, satri-cel offers patients the opportunity to break free from the constraints of frequent hospital visits for treatment, achieving a leap from ‘prolonging survival’ to ‘improving quality of life.’ As the world’s first successfully marketed CAR-T therapy for solid tumors, satri-cel not only fills the gap in later-line treatment for advanced gastric cancer but also ushers in a new era of cellular therapy for solid tumors. This breakthrough lays a critical foundation for advancing frontline therapy and combination treatment strategies, and is expected to reshape the treatment landscape of gastric cancer and even gastrointestinal tumors. We believe that with the promotion of clinical application, this innovative therapy will illuminate new hope for life for the vast number of gastric cancer patients.”

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, “The approval and launch of satri-cel is an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors. This would not have been possible without the trust and support of the patients and their families who participated in the clinical trials, the investigator teams, partners, regulatory agencies, and relevant departments. We will go all out to advance the clinical application and market access of satri-cel, ensuring that this innovative therapy benefits Chinese patients widely and in a timely manner. At the same time, we will strive to expand this product to more countries and regions to meet greater medical needs. In addition, we are also exploring first-line sequential therapy and postoperative adjuvant therapy for advanced gastric cancer, with the aim of helping more patients achieve deeper therapeutic benefits and even the possibility of cure.”

About Satri-cel

Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June, 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.

The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

[1] World Health Organization (WHO). International Agency for Research on Cancer. Cancers Fact Sheet (Globocan 2022). Cancer Today (who.int). Last accessed 22-May-2024.

[2] International Agency for Research on Cancer. (2021). Stomach fact sheet. IARC Global Cancer Observatory.

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.

[4] B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Center, 4 (1) (2024), pp. 47-53.

[5] Zhao, Lulu, et al. “Changing Landscape in Stage, Treatment and Survival of Gastric Cancer in China 1998–2022: Insights of 40,158 Patients from the National Gastric Cancer Cohort.” Cancer Letters, vol. 642, 2026, p. 218261. DOI: 10.1016/j.canlet.2026.218261.

[6] Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025 Jun 7;405(10494):2049-2060. doi: 10.1016/S0140-6736(25)00860-8. Epub 2025 May 31. PMID: 40460847.

Contact CARsgen
For more information, please visit https://www.carsgen.com/
Public Relations: PR@carsgen.com
Investor Relations: IR@carsgen.com 

State Grid Lintao Power Supply Company: Power Illuminates Millennia-Old Ceramic Charm, Craftsmanship Safeguards the Torch of Intangible Cultural Heritage

By
Advertorial Desk
-

DINGXI, China, June 22, 2026 /PRNewswire/ — The millennia-long ceramic art of Majiayao unfolds like poetry, nourished by the cultural heritage nurtured by the Taoshui River stretching a hundred li. As a vital booster for the inheritance of intangible cultural heritage, power lays a solid foundation for the growth of local cultural industries. Recently, State Grid Lintao Power Supply Company took proactive responsibility and delivered targeted energy support. Its staff conducted routine equipment inspections at Lintao Xinyuan Antique Pottery Development Co., Ltd., wholeheartedly safeguarding the steady development of the intangible cultural heritage industry and reviving traditional culture with consistent, reliable power supply.

Stable Power Guarantees Upgraded Development of Intangible Cultural Heritage Industries

Lintao Xinyuan Antique Pottery Development Co., Ltd. is a key local enterprise carrying forward the Majiayao pottery craftsmanship. Its entire production process relies on electrical machinery, including clay mixers, clay kneaders, wheel-throwing machines, trimming lathes and electric kilns. These complete sets of equipment impose stringent requirements on power quality and voltage stability. Particularly during firing in electric kilns, voltage fluctuations or unexpected power outages will easily disrupt temperature control inside kilns, resulting in mass scrapping of pottery works and irreversible economic losses for the enterprise.

The company provides exclusive one-on-one services via district managers and includes the pottery firm in the streamlined power service system for micro and small enterprises. Workers regularly visit the workshop to identify hidden electrical risks in power lines, switches and kiln facilities. A dedicated power guarantee mechanism for key customers has been established, featuring periodic equipment patrols and infrared temperature detection. Comprehensive emergency repair plans are refined to enable rapid response and expedited troubleshooting of sudden faults, fully securing stable operation of this intangible cultural heritage enterprise.

Power Accelerates the Construction of Cultural Venues

Beyond supporting the production of heritage crafts, the power company also fuels the development of cultural exhibition spaces. The Lintao Majiayao Culture Research & Exhibition Center serves as a core provincial and national platform for inheriting, displaying and promoting Majiayao intangible cultural heritage.

During the project’s construction phase, the company assigned dedicated staff to provide frontline customized services, listing the venue as a priority cultural livelihood project. It tailored a targeted power supply scheme and opened a green channel for power application procedures, streamlining approval steps and shortening processing cycles. The supporting power expansion project was finished 15 days ahead of schedule: two 500kVA dedicated transformers were newly installed, alongside high-voltage metering devices and intelligent switchgears, with 75 meters of dedicated power lines erected. These facilities form a robust power foundation for daily venue operation and cultural exhibitions.

Power Empowers Intangible Heritage, Ingenuity Passes Down Civilization

Moving forward, State Grid Lintao Power Supply Company will continue to deepen power services for cultural tourism and intangible heritage sectors while optimizing the business environment. With premium, efficient and dependable power support, the company will keep lighting the path of Majiayao cultural inheritance, allowing the thousand-year ceramic charm to shine brilliantly and endure perpetually in the new era.

State Grid Zhang County Power Supply Company Delivers Safety Services On-Site to Secure Power for Agricultural Product Processing

By
Advertorial Desk
-

DINGXI, China, June 22, 2026 /PRNewswire/ — On June 16, staff from State Grid Zhang County Power Supply Company conducted special on-site safety power services at fruit and vegetable storage facilities, grain processing sites and small agricultural product workshops across its service area, reinforcing the safety barrier for electricity use in agriculture.

As summer arrives, self-operated farm processing equipment for grain threshing, fruit and vegetable fresh-keeping, small-scale oil pressing, drying and other operations are put into intensive use, driving a sharp rise in power load. Hidden hazards such as aging power lines and unauthorized random wiring may easily trigger safety incidents. Company staff visited every household to conduct thorough inspections of incoming lines, sockets, residual current operated protective devices and wiring of processing machinery inside farm premises. They rectified on the spot risks including aged circuits, exposed bare wires and illegally erected temporary wiring, and replaced damaged switches and aging power strips free of charge to eliminate potential electrical dangers at the source.

Between maintenance and inspection work, in line with the publicity requirements of the national Work Safety Month, staff delivered easy-to-understand lectures to farmers covering safe electricity use during thunderstorms, standardized operation of high-power processing equipment, and emergency response to electrical fires. Brochures on safe power consumption were handed out simultaneously to warn farmers against overloading circuits and unauthorized wiring. These efforts helped raise farmers’ awareness of safe electricity use and prevent electric shocks and electrical fires.

To meet summer power guarantee demands for agricultural production, the company stepped up patrol frequency on 10-kilovolt power lines and distribution transformers surrounding rural processing sites, intensified clearance of tree obstructions under power lines, and completed flood control renovations for low-lying flood-prone power facilities in advance. Sufficient maintenance supplies and emergency power generation equipment were also fully stocked to minimize production disruptions caused by power outages and guarantee stable electricity supply for processing operations.

Furthermore, leveraging its grid-based service system, the company established dedicated electricity consumption ledgers for crop growers and livestock farmers, streamlined fault reporting channels, and enforced a 24-hour emergency repair on-duty system to ensure timely resolution of any power failures encountered by farmers.

Moving forward, State Grid Zhang County Power Supply Company will further expand its convenient service scope, carry out regular household electrical hazard inspections and safety publicity campaigns, support stable output and higher incomes for farmers via reliable and consistent power supply, and inject electric power momentum into rural revitalization.

HKSTP Forges An Asia–Europe Innovation Gateway at VivaTech 2026

By
Advertorial Desk
-

A stream of partnership propose heightened tech and business connections across continents


HONG KONG / PARIS, FRANCE – Media OutReach Newswire – 22 June 2026 – Hong Kong Science and Technology Parks Corporation (HKSTP) has successfully concluded its Paris delegation to Viva Technology (VivaTech) 2026, which celebrated its 10th anniversary as a global stage for ambitious startups from June 17 to 20. HKSTP reinforces its impactful role as Asia’s I&T ecosystem orchestrator, by confirming the signing of multiple memorandums of understanding (MOU) between Park companies and the European I&T community:

  • Microalgae expert Algreen, signed with ForNatures, a South Korean Climate Tech company that specialises in carbon capture management, in amplifying mutual research and development capabilities to take a step closer to ESG goals.
  • Robotics solutions provider Robocore, signed with ARCHTYP, a Slovenian cognitive software startup, enabling the display of a differentiating layer on a proven platform to reach market demands, while also closing deals with French advertising guru JCDecaux, to supply a thousand robots and extend its reach in the European market.
  • The appeal and use cases of LeafIoT‘s green asset management has caught the eyes of European’s professionals in the preservation sector, including the French Agricultural Research Centre for International Development (CIRAD), the Catalonian landscaping and environmental restoration company Gremi de Jardineria de Catalunya, and notably, Professor Andrea Galli from the Laboratory of Geotechnical Analysis and Modelling (GeoT-LAM) at Politecnico di Milano, all taking solid steps in exploring new opportunities and breakthroughs and boosts in market reach.
An Asia-Europe innovation gateway forging forward at VivaTech 2026 with an influx of partnerships propose heightened tech and business connections across the world.
An Asia-Europe innovation gateway forging forward at VivaTech 2026 with an influx of partnerships propose heightened tech and business connections across the world.

The annual showcase put a spotlight on enabling founders to connect with the local I&T community, explore market access, and forge global partnerships via pitching and matching sessions, networking mixers, and investor engagement. Compared with VivaTech 2025, this year’s delegation achieved even stronger momentum with over 50% growth in opportunities, totalling more than 200 potential business leads worth HK$70M in total.

HKSTP’s growing presence at VivaTech reflects its mission to open new doors for Hong Kong’s startups, build pathways into European markets and create reciprocal opportunities for European innovators to enter Asia through Hong Kong’s strategic location in the world’s No.1 innovation cluster – Guangdong-Hong Kong-Macao GBA (World Intellectual Property Organisation Innovation Index).

Terry Wong, CEO of HKSTP, said: “France and the EU represent critical opportunities for Hong Kong and Chinese Mainland I&T ventures to scale globally. VivaTech provides a world-class platform for collaboration, co-creation, and knowledge exchange. Our strong ties with French partners underline the importance of Hong Kong as a global launchpad for innovation, supporting startups on their journey from local success to international impact.”

Highlights this year include the expansion of HKSTP’s partnership with Bouygues Construction, a global leader in sustainable construction and infrastructure headquartered in France, and operates across more than 60 countries and is recognised for delivering major projects in transport, energy, real estate, and smart cities.

Through its Hong Kong arm, Dragages Hong Kong, Bouygues has maintained a 70-year legacy in Hong Kong, contributing to iconic infrastructure projects and championing innovation in areas such as construction safety, modular design, green materials, and site automation. HKSTP is the first and only institution in Hong Kong to bridge tech venture directly into the Bouygues Construction “Scale One: programme, providing a fast track to prototyping and commercialisation. This initiative sets a new benchmark for cross-border industrial innovation partnerships, accelerating global impact for Hong Kong startups through trusted collaborations with leading European enterprises.

Building on existing strong foundations, Bouygues Construction is now stepping up collaboration with HKSTP beyond Asia, offering selected Hong Kong startups the chance to showcase solutions at Bouygues’ headquarters in France, with opportunities for solution validation and pilot trials across European operations.

The Hong Kong Tech Pavilion, organised by the Hong Kong Trade Development Council (HKTDC) and supported by partners including HKSTP, showcased market-ready solutions spanning AI, green- and health tech from 24 tech ventures, and marked a major milestone in creating a direct bridge between Hong Kong and Europe’s heart of innovation and technology.
Hashtag: #HKSTP

The issuer is solely responsible for the content of this announcement.

HKSTP

More information about HKSTP is available at .

CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors

By
Advertorial Desk
-

SHANGHAI, June 22, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration (“NMPA”) today, the New Drug Application (“NDA”) of satricabtagene autoleucel (“satri-cel”), the proprietary autologous humanized Claudin18.2 CAR T-cell therapy product, was approved for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy. Satri-cel is the world’s first approved CAR T-cell therapy product for the treatment of solid tumors.

Gastric cancer is one of the malignancies with the highest disease burden worldwide, ranking fifth in both incidence and mortality globally, with approximately 970,000 new cases and 660,000 deaths annually[1]. More than 70% of new and fatal cases occur in Asia[2], and Chinese patients account for approximately 47% of the global gastric cancer burden[3]. According to statistics from the National Cancer Center of China, there were approximately 360,000 new cases and 260,000 deaths from gastric cancer in China in 2022, ranking fifth in cancer incidence and third in cancer-related mortality[4]. Despite continuous advances in surgical techniques and comprehensive treatment modalities, gastric cancer is insidious in onset. In China, the proportion of early-stage gastric cancer diagnosis remains below 20%, and the 5-year survival rate for advanced gastric cancer is only about 10%[5]. Gastric cancer is characterized by high incidence, low early diagnosis rate, high heterogeneity, and high mortality. Conventional chemotherapy drugs have reached a plateau, targeted therapy options are limited, and the proportion and magnitude of benefit from immunotherapy still urgently need to be improved. Therefore, patients with unresectable or metastatic gastric cancer still face substantial unmet medical needs, and there is an urgent demand to drive the discovery and exploration of more precision therapies and novel anti-tumor agents.

Claudin18.2 is a highly selective marker protein. Its expression in normal healthy tissues is very limited, occurring only in differentiated gastric mucosal epithelial cells, whereas it is highly expressed in gastric cancer and other malignant tumors. Satri-cel is an autologous CAR-T cell product targeting Claudin18.2. It is genetically modified to express a CAR construct consisting of a humanized Claudin18.2-specific single-chain monoclonal antibody fragment (hu8E5-2I), a CD8α hinge region, a CD28 transmembrane region, a CD28 intracellular signaling domain (CD28 ICD), and a CD3ζ intracellular signaling region. To our knowledge, we were the first in the world to successfully identify, validate, and report the solid tumor-associated antigen Claudin18.2 as a valid target for CAR T-cell therapy. To further address the challenges of the tumor microenvironment in treating solid tumors, the company independently developed an innovative, patent-protected preconditioning regimen which is to be administered prior to infusion of satri-cel. This regimen features the addition of low-dose nab-paclitaxel to the conventional lymphodepletion regimen comprising cyclophosphamide and fludarabine to enhance the infiltration and anti-tumor efficacy of CAR T cells. The Company has implemented global patent layout around satri-cel, covering the target, indications, dosage, and preconditioning regimens, among others.

The clinical efficacy of satri-cel has received authoritative recognition from top international medical journals. The results of its confirmatory randomized controlled study have been published in The Lancet [6]. Clinical data show that among patients with advanced, heavily pretreated G/GEJ cancer who have extremely limited treatment options and a very poor prognosis, satri-cel demonstrated significant efficacy benefit and a good safety profile compared to existing treatments, bringing a new treatment option to patients with advanced gastric cancer. This major breakthrough not only establishes a new standard for CAR-T therapy in solid tumors but also lays a solid scientific foundation for advancing to earlier lines of therapy, exploring combination treatment regimens, and expanding applications to other Claudin18.2-positive solid tumors such as pancreatic cancer and biliary tract cancer.

Professor Lin Shen’s team at Peking University Cancer Hospital led the clinical studies of satri-cel. Professor Shen commented, “For patients with advanced G/GEJA who have failed multiple lines of prior therapy, previous treatment options were extremely limited and the prognosis was very poor. The approval of satri-cel provides us with a novel and effective therapeutic weapon. This product has brought clinically meaningful and significant benefits to such patients, with remarkable efficacy that is difficult to achieve with existing treatment modalities. More importantly, as a CAR-T product, satri-cel offers patients the opportunity to break free from the constraints of frequent hospital visits for treatment, achieving a leap from ‘prolonging survival’ to ‘improving quality of life.’ As the world’s first successfully marketed CAR-T therapy for solid tumors, satri-cel not only fills the gap in later-line treatment for advanced gastric cancer but also ushers in a new era of cellular therapy for solid tumors. This breakthrough lays a critical foundation for advancing frontline therapy and combination treatment strategies, and is expected to reshape the treatment landscape of gastric cancer and even gastrointestinal tumors. We believe that with the promotion of clinical application, this innovative therapy will illuminate new hope for life for the vast number of gastric cancer patients.”

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen, stated, “The approval and launch of satri-cel is an important milestone event marking the advancement of CAR-T cell therapy from hematologic malignancies to solid tumors. This would not have been possible without the trust and support of the patients and their families who participated in the clinical trials, the investigator teams, partners, regulatory agencies, and relevant departments. We will go all out to advance the clinical application and market access of satri-cel, ensuring that this innovative therapy benefits Chinese patients widely and in a timely manner. At the same time, we will strive to expand this product to more countries and regions to meet greater medical needs. In addition, we are also exploring first-line sequential therapy and postoperative adjuvant therapy for advanced gastric cancer, with the aim of helping more patients achieve deeper therapeutic benefits and even the possibility of cure.”

About Satri-cel

Satri-cel is an autologous CAR T-cell therapy product against the protein Claudin18.2 that is the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors. It was approved by the NMPA in June, 2026 for the treatment of Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy, making it the world’s first approved CAR T-cell therapy product for solid tumors.

The Company is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China (NCT05911217), an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA (NCT06857786) and an IIT for sequential therapy following first-line treatment for G/GEJA (NCT07179484).

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

[1] World Health Organization (WHO). International Agency for Research on Cancer. Cancers Fact Sheet (Globocan 2022). Cancer Today (who.int). Last accessed 22-May-2024.

[2] International Agency for Research on Cancer. (2021). Stomach fact sheet. IARC Global Cancer Observatory.

[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.

[4] B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Center, 4 (1) (2024), pp. 47-53.

[5] Zhao, Lulu, et al. “Changing Landscape in Stage, Treatment and Survival of Gastric Cancer in China 1998–2022: Insights of 40,158 Patients from the National Gastric Cancer Cohort.” Cancer Letters, vol. 642, 2026, p. 218261. DOI: 10.1016/j.canlet.2026.218261.

[6] Qi C, Liu C, Peng Z, Zhang Y, Wei J, Qiu W, Zhang X, Pan H, Niu Z, Qiu M, Qin Y, Fang W, Ye F, Li N, Liu T, Liu A, Zhang X, Hu C, Zhang J, Cui J, Lin X, Wang S, Zhang J, Lin T, Qu X, Yuan X, Gong J, Li J, Gao W, Gai L, Wang Y, Yuan D, Li Z, Shen L. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025 Jun 7;405(10494):2049-2060. doi: 10.1016/S0140-6736(25)00860-8. Epub 2025 May 31. PMID: 40460847.

 

State Grid Lintao Power Supply Company: Power Nourishes Green Farmlands, Care Safeguards Rural Summer Safety

By
Advertorial Desk
-

DINGXI, China, June 22, 2026 /PRNewswire/ — Early summer brings vigorous growth of all living things and busy farm work in the fields. To meet the electricity demand of summer agricultural production and fully guarantee reliable power supply for farmland irrigation and facility agriculture in early summer, State Grid Lintao Power Supply Company made advance arrangements and took proactive actions on June 18. Focusing on the critical summer peak power supply period, the company dispatched staff to farmlands across all townships to accurately match farmers’ power needs. With high-quality power supply and thoughtful services, it provided solid backing for summer agricultural production.

“Right now is the crucial power-consuming period for vegetable greenhouse maintenance and farmland irrigation. Sufficient power and considerate services give us greater confidence in farming,” said Wang Quanhu, a villager from the 4th Group of Sanxian Village, Manwa Township.

As early summer witnesses both booming agricultural production and tight power guarantee, the company’s rural revitalization task force stationed in Manwa Township took the initiative to visit farmlands every day to precisely survey farmers’ electricity demands. For large-scale growers and facility agricultural bases, the team offered exclusive power guidance, while helping tackle practical difficulties in agricultural supplies and farming techniques. Agricultural technicians were invited to give on-site demonstrations to guide scientific planting and efficient power consumption. Meanwhile, comprehensive publicity on safe agricultural electricity use and hidden danger inspections were carried out, with zero-distance door-to-door services delivered to build a solid safety barrier for power use in agricultural production.

In line with the summer peak power guarantee plan and local agricultural conditions in Lintao County, the company opened a green channel for agricultural power consumption. Relying on rural power service grids and WeChat service groups for each village, the team tracked farmers’ electricity demands in real time through online and offline coordination. Power application procedures were streamlined with priority acceptance and connection, ensuring instant application and rapid response for agricultural power needs.

The company conducted full-coverage safety inspections on farmland motor-pumped wells, irrigation power lines and greenhouse power distribution facilities within its jurisdiction, troubleshooting defects well by well and equipment by equipment. It strived to ensure stable and reliable irrigation power in early summer and during high-temperature peak loads, letting farmers irrigate and use electricity without worries. Solid power support was delivered to advance high-standard farmland construction and secure stable grain output and increased farmers’ income.

Take early actions for summer peak power supply; empower agriculture with electricity to boost rural revitalization.

Going forward, State Grid Lintao Power Supply Company will stay fully committed to power guarantee, earnestly safeguard grid operation in early summer and optimize agricultural power services. Full-power supply will guard bumper harvests of farmlands, injecting strong momentum into rural revitalization in Lintao County.

1...213214215...6,463Page 214 of 6,463